Keros Therapeutics KROS Income Statement (2019-2026)

NASDAQ KROS
$10.95 -0.15 (-1.31%)
As of: Aug 20, 2026 · 3:59 PM EDT
Income Statement Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Jun2026
Revenue & cost
Revenue (Quarter)
0.10M17.90M18.00M0.01M0.14M0.08M0.39M3.04M211.25M18.17M14.12M0.19M
Operating items
Research & Development (Quarter)
9.98M14.83M18.83M18.08M23.28M21.04M24.87M31.09M32.53M34.14M37.49M38.26M40.52M49.23M45.63M48.71M43.50M19.52M17.91M22.33M
Selling, General & Administrative (Quarter)
5.66M5.37M6.03M6.05M7.45M6.94M7.09M7.78M8.80M9.15M9.11M10.31M9.96M9.82M10.66M10.50M14.48M10.13M11.74M8.61M
Other Operating Expenses (Quarter)
Operating Expenses (Quarter)
15.64M20.20M24.87M24.13M30.73M27.98M31.96M38.87M41.34M43.29M46.60M48.57M50.48M59.05M56.30M59.21M57.98M29.65M29.66M30.94M
Operating Income (Quarter)
-15.54M-20.20M-4.87M-24.13M-30.73M-27.98M-31.96M-38.87M-41.34M-43.28M-46.45M-48.48M-50.44M-58.66M-53.25M152.04M-39.82M-15.38M-29.27M-30.94M
EBIT (Quarter)
-15.54M-20.20M-4.87M-24.13M-30.73M-27.98M-31.96M-38.87M-41.34M-43.28M-46.45M-48.48M-50.44M-58.66M-53.25M152.04M-39.82M-15.38M-29.27M-30.94M
Non-operating items
Other Non Operating Income (Quarter)
-0.08M-0.14M-0.10M-0.06M0.09M0.76M-1.40M-0.04M-0.15M-0.07M0.06M-0.44M-0.20M-0.09M-0.23M-0.34M-0.22M-0.25M0.27M-0.06M
Non Operating Income (Quarter)
-0.08M-0.14M-0.07M-0.06M3.46M4.47M2.24M3.06M3.83M3.84M6.21M5.37M5.18M5.70M7.53M6.45M6.90M6.68M4.29M2.23M
Net income details
EBT (Quarter)
-15.62M-20.34M-4.94M-24.19M-27.27M-23.51M-29.72M-39.37M-91.44M-76.88M-45.58M-43.11M-45.26M-52.96M-45.73M158.49M-32.92M-8.70M-24.98M-28.71M
Tax Provisions (Quarter)
-0.04M2.00M0.30M10.04M-2.22M-1.42M-1.51M
Profit After Tax (Quarter)
-15.62M-20.30M-6.94M-24.19M-27.27M-23.51M-29.72M-35.80M-37.51M-39.44M-40.24M-43.11M-45.26M-52.96M-46.03M148.45M-30.70M-7.28M-23.46M-28.71M
Income from Continuing Operations (Quarter)
-15.62M-20.30M-6.94M-24.19M-27.27M-23.51M-29.72M-39.37M-91.44M-76.88M-45.58M-43.11M-45.26M-52.96M-46.03M148.45M-30.70M-7.28M-23.46M-28.71M
Consolidated Net Income (Quarter)
-15.62M-20.30M-6.94M-24.19M-27.27M-23.51M-29.72M-39.37M-91.44M-76.88M-45.58M-43.11M-45.26M-52.96M-46.03M148.45M-30.70M-7.28M-23.46M-28.71M
Income towards Parent Company (Quarter)
-15.62M-20.30M-6.94M-24.19M-27.27M-23.51M-29.72M-39.37M-91.44M-76.88M-45.58M-43.11M-45.26M-52.96M-46.03M148.45M-30.70M-7.28M-23.46M-28.71M
Net Income towards Common Stockholders (Quarter)
-15.62M-20.30M-6.94M-24.19M-27.27M-23.51M-29.72M-35.80M-37.51M-39.44M-40.24M-43.11M-45.26M-52.96M-46.03M148.45M-30.70M-7.28M-23.46M-28.71M
Additional items
EPS (Basic) (Quarter)
-0.67-0.87-0.30-1.01-1.13-0.92-1.18-1.26-1.27-1.33-1.37-1.21-1.25-1.41-1.233.66-0.76-0.18-0.63-1.45
EPS (Diluted) (Quarter)
-0.67-0.87-0.30-1.01-1.13-0.92-1.18-1.26-1.27-1.33-1.37-1.21-1.25-1.41-1.233.62-0.76-0.18-0.62-1.45
Shares Outstanding (Quarter)
23.31M23.36M23.33M23.99M24.05M25.55M25.24M28.37M29.60M29.67M29.45M35.69M36.10M37.59M37.44M40.56M40.61M40.62M37.22M19.80M
Shares Outstanding (Diluted) (Quarter)
23.31M23.36M23.33M23.99M24.05M25.55M25.24M28.37M29.60M29.67M29.45M35.69M36.10M37.59M37.44M41.02M40.61M40.62M37.86M19.80M
Shares Outstanding (Entity) (Quarter)
23.33M23.40M23.97M24.00M24.43M26.08M27.54M29.55M29.66M29.68M31.84M36.07M36.17M39.26M40.55M40.56M40.62M40.63M40.67M19.83M
EBITDA (Quarter)
-15.54M-20.20M-4.87M-24.13M-30.73M-27.98M-31.96M-38.87M-41.34M-43.28M-46.45M-48.48M-50.44M-58.66M-53.25M152.04M-39.82M-15.38M-29.27M
Interest Expenses (Quarter)
71.59M59.49M0.00M0.20M30.40M47.90M0.21M0.50M50.10M33.60M-0.88M134.60M54.40M93.50M0.91M4.60M5.40M6.50M97.99M
Tax Rate (Quarter)
0.19%-40.46%-0.66%6.34%6.75%16.36%6.06%